.png){kind=logo}
Hemostemix Clinical Trials
Advancing science. Inspiring hope.
Hemostemix is committed to building our base of scientific research on ACP-01 autologous stem cells. Our goal is to bring new scientific breakthroughs and therapeutic options to market to help transform lives of patients living with ischemic related diseases.
This site will help you understand more about our clinical trials so you can make informed - decisions about participation for yourself or a loved one.
Get Notified About Upcoming Clinical Trials
We are planning to field new clinical studies to assess the safety and efficacy of ACP-01 in the treatment of a variety of diseases.
Part of the study process includes securing approval by an Institutional Review Board, which under FDA regulations, is group that has been formally designated to review and monitor biomedical research involving human subjects.
Once a study has been approved, we can notify you that the recruitment window is open and confirm eligibility requirements.
If you’d like to be notified when a study is open for enrollment, please complete the notification form below.
These studies will be investigational and the therapies under evaluation have not been approved for general use.
Submitting this form expresses interest only — it does not enroll you in a study, guarantee eligibility, or promise access to treatment. Final eligibility will be determined by the study protocol and an IRB-approved informed consent process.
About Hemostemix
Hemostemix (TSXV:HEM OTCQB:HMTXF FSE:2VFO) is an autologous stem cell therapy platform company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has developed and patented ACP-01 - an autologous (patient's own) blood-based stem cell therapy. Hemostemix has completed seven clinical studies of 318 subjects and published its results in 11 peer reviewed publications.
For further information, please contact: Thomas Smeenk, President, CEO & Co-Founder: EM: tsmeenk@hemostemix.com